Voyager Therapeutics (VYGR) EBITDA Margin (2015 - 2026)
Voyager Therapeutics (VYGR) posted EBITDA Margin of 1167.37% for Q1 2026, down 499.6% sequentially from 194.69% in Q4 2025, and down 63141.0% YoY from N/an in Q1 2025.
Voyager Therapeutics (VYGR) EBITDA Margin (2015 - 2026) Analysis & Trends
Voyager Therapeutics has reported EBITDA Margin for 12 years, with the latest figure at 1167.37% in Q1 2026.
- Quarterly EBITDA Margin fell 63141.0% year-over-year to 1167.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 348.79% (down 19681.0% YoY) and the FY2025 annual result came in at 326.56%, down 22245.0% from the prior year.
- EBITDA Margin fell to 1167.37% in Q1 2026 per VYGR's latest filing, from 194.69% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1584.71% in Q4 2022 and troughed at 3244.68% in Q1 2022.
- A 5-year average of 528.85% and a median of 228.91% in 2025 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin tumbled 285106 bps in 2022, then soared 332634 bps in 2023.
- Over 5 years, EBITDA Margin stood at 1584.71% in 2022, then sank by 96 bps to 60.0% in 2023, then plunged by 1113 bps to 607.82% in 2024, then soared by 68 bps to 194.69% in 2025, then sank by 500 bps to 1167.37% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 1167.37%, 194.69%, and 228.91% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | -824.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -824.75% |
| Mar 31, 2026 | -1,167.37% |
| Dec 31, 2025 | -194.69% |
| Sep 30, 2025 | -228.91% |
| Jun 30, 2025 | -704.33% |
| Mar 31, 2025 | -535.96% |
| Dec 31, 2024 | -607.82% |
| Sep 30, 2024 | -55.95% |
| Jun 30, 2024 | -50.80% |
| Mar 31, 2024 | -82.99% |
| Dec 31, 2023 | 60.00% |
| Sep 30, 2023 | -639.51% |
| Jun 30, 2023 | -518.90% |
| Mar 31, 2023 | 81.66% |
| Dec 31, 2022 | 1,584.71% |
| Sep 30, 2022 | 35.15% |
| Jun 30, 2022 | -2,720.08% |
| Mar 31, 2022 | -3,244.68% |
| Dec 31, 2021 | 20.31% |
| Sep 30, 2021 | -1,696.76% |